Telo Genomics Corp Stock Fundamentals

3D0A Stock  EUR 0.06  0.03  93.44%   
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Telo Genomics Corp Company Shares Owned By Insiders Analysis

Telo Genomics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Telo Genomics Shares Owned By Insiders

    
  6.52 %  
Most of Telo Genomics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telo Genomics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 6.524% of Telo Genomics Corp are shares owned by insiders. This is 57.02% lower than that of the Healthcare sector and 57.58% lower than that of the Diagnostics & Research industry. The shares owned by insiders for all Germany stocks is 35.34% higher than that of the company.

Telo Genomics Corp Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telo Genomics competition to find correlations between indicators driving Telo Genomics's intrinsic value. More Info.
Telo Genomics Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.

Telo Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.
Telo Genomics is currently under evaluation in shares owned by insiders category among its peers.

Telo Fundamentals

About Telo Genomics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada. TELO GENOMICS operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange.

Currently Active Assets on Macroaxis

Other Information on Investing in Telo Stock

Telo Genomics financial ratios help investors to determine whether Telo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.